E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
metastatic renal cell carcinoma, second line therapy after failure of one VEGF-TKI targeted therapy |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10050513 |
E.1.2 | Term | Metastatic renal cell carcinoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to assess the rate of patients who are free of disease progression after 6 months of treatment with everolimus. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are:
- Estimate the progression free survival of patients treated with everolimus after having progressed on or after one VEGF-targeted therapy - To assess overall survival of patients treated with everolimus after failure of one VEGF-targeted therapy. - To assess the overall response rate (ORR) according to RECIST-criteria and the duration of response - To assess the safety profile of everolimus after failure of one VEGF-targeted therapy
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Titel: "DCI-MRI substudy", Version 1.0 date 06.10.2010 (inlcuded in study protocol) |
|
E.3 | Principal inclusion criteria |
Each patient must meet the following criteria to be enrolled: 1. Provide written informed consent 2. Aged 18 years and above 3. Histologically or cytologically confirmed predominantly clear cell renal cell carcinoma 4. Metastatic disease documented by CT or MRI (histological confirmation not mandatory but wishful) 5. Patients with or without nephrectomy (partial or total) 6. Patients with at least one measurable lesion at baseline according to RECIST criteria 1.1 7. Failure of exactly one prior VEGFR-TKI therapy (e.g. sunitinib, sorafenib, pazopanib) for metastatic renal cell carcinoma 8. ECOG 0-2 9. Hemoglobin ≥ 9.0 g/dL 10. Platelet count ≥75,000/μL 11. Absolute neutrophil count ≥1,5x109/l 12. Serum creatinine < 2.5 x ULN 13. Liver function: Serum bilirubin ≤ 1.5 x ULN, AST or ALT ≤ 2.5 x ULN. For patients with liver metastasis: AST and ALT ≤ 5x ULN 14. Able to swallow the study drug whole as a tablet 15. Expected life expectancy of at least 6 months 16. Women of childbearing potential must have had a negative serum pregnancy test within 14 days prior to the administration of the study treatment or must have a documented condition that prohibits pregnancy (e.g. hysterectomy, post-menopausal).
|
|
E.4 | Principal exclusion criteria |
Patients who meet any of the following criteria will be excluded from the study: 1. Patients who have received >1 prior VEGFR-TKI therapy or prior therapy with bevacizumab +/- interferon. 2. VEGFR-TKI therapy within 14 days prior to start of study drug 3. Patients who have previously received systemic mTOR inhibitors (sirolimus, temsirolimus, everolimus). 4. Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients. 5. Any condition which, in the opinion of the investigator, would preclude participation in this trial 6. Patients within 4 weeks post-major surgery (e.g., intra-thoracic, intra-abdominal or intrapelvic), open biopsy, or significant traumatic injury to avoid wound healing complications. Minor procedures and percutaneous biopsies or placement of vascular access device require 7 days prior to study entry. 7. Patients who had radiation therapy as part of the curative treatment within 4 weeks prior to start of study treatment. Palliative radiotherapy to bone lesions within 2 weeks prior to study treatment start. 8. Patients in anticipation of the need for major surgical procedure during the course of the study. 9. Patients with a serious non-healing wound, ulcer, or bone fracture. 10. Patients with a history of seizure(s) not controlled with standard medical therapy. 11. History or clinical evidence of central nervous system (CNS) metastases. Subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and meet all 3 of the following criteria are eligible: a) are asymptomatic and, b) have had no evidence of active CNS metastases for ≥ 3 months prior to enrolment (inactive/controlled CNS metastases are allowed) and, c) have no requirement for steroids or enzyme-inducing anticonvulsants (e.g. carbamazepine, phenobarbital, phenytoin) 12. Patients receiving chronic systemic treatment with corticosteroids (dose of > 10 mg/day methylprednisone equivalent) or another immunosuppressive agent. Inhaled and topical steroids are acceptable. 13. Poorly controlled diabetes as defined by fasting serum glucose >2.0 x ULN. 14. Active (acute or chronic) or uncontrolled infection of bacterial, mycotic or viral genesis. 15. Liver disease such as chronic active hepatitis or chronic persistent hepatitis. 16. Impaired liver function classified as Child-Pugh class C. 17. Patients with a known history of HIV seropositivity. 18. Patients with active bleeding disorders. 19. Patients who have any severe and/or uncontrolled medical conditions or other conditions within the past 12 months that could affect their participation in the study or any disorders that impair the ability to evaluate the patient or for the patient to complete the study according to the investigators assessment. 20. Patients who have a history of another primary malignancy and off treatment for ≤ 3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of the uterine cervix or breast, and localized cancer of the bladder (T1) and prostate (T1 - T2). 21. Female patients who are pregnant or breast feeding. 22. Men and women of reproductive potential who are not using highly effective birth control methods. Oral contraceptives for female patients and barrier contraceptives are not acceptable. For definition of highly effective birth control methods please refer to section 12.3.6 of this protocol. 23. Patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start. 24. Patients unwilling or unable to comply with the protocol. 25. Exclusion criteria for MRI: intracorporal metal (e.g. uncompatible heart valves, pacemakers), contrast media allergy, claustrophobia
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Rate of patients progression free 6 months after start of study treatment. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
8 month after accrual of the last patient |
|
E.5.2 | Secondary end point(s) |
- Progression free survival, - Overall survival - Objective response rate - Incidence of adverse events, serious adverse events, incidence of laboratory abnormalities (hematology, blood chemistry and urinalysis
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
End of Study (at latest September 2017) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the trial is defined as last visit of the last patient or at latest Septemper 2017. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |